Sale!

HLA Single Antigen Bead Assay for Class II IgG Antibodies DSA-SAB Class II Test Cost

Original price was: 5,200 د.إ.Current price is: 4,680 د.إ.

-10%

The HLA Single Antigen Bead (SAB) Assay for Class II IgG Antibodies, also known as the DSA-SAB Class II Test, is a highly specialized laboratory test performed to detect and identify specific antibodies directed against Human Leukocyte Antigen (HLA) Class II molecules. This test is crucial in the field of transplantation medicine, as the presence of these donor-specific antibodies (DSA) can significantly impact the success of organ transplants, particularly in kidney and bone marrow transplants. The assay utilizes microbeads coated with purified HLA Class II antigens, allowing for the precise identification of antibodies against these antigens in the patient’s serum.

Conducted at DNA Labs UAE, a leading diagnostic and research facility, the test employs state-of-the-art technology to ensure accurate and reliable results. The cost of the test is 4680 AED, reflecting the complexity and the specialized nature of the assay. This test is instrumental for clinicians in making informed decisions regarding organ transplantation, including assessing the risk of rejection and guiding immunosuppressive therapy. Patients undergoing evaluation for transplantation or those who have received a transplant may be recommended to undergo this test as part of their treatment and monitoring plan.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

HLA Single Antigen Bead Assay for Class II IgG Antibodies DSA-SAB Class II Test

Test Cost: AED 4680.0

Symptoms, Diagnosis, and Test Details

The HLA Single Antigen Bead Assay for Class II IgG antibodies (DSA-SAB Class II Test) is a laboratory test used in transplantation medicine to detect and identify specific antibodies against human leukocyte antigens (HLA) in the blood of transplant recipients.

HLA molecules are proteins found on the surface of cells that help the immune system distinguish between self and non-self cells. In transplantation, it is important to match the HLA antigens between the donor and recipient to minimize the risk of rejection. However, sometimes the recipient may develop antibodies against the donor’s HLA antigens, known as donor-specific antibodies (DSA), which can increase the risk of rejection and graft failure.

The DSA-SAB Class II Test specifically focuses on detecting and identifying IgG antibodies against Class II HLA antigens. Class II HLA antigens are found on antigen-presenting cells, such as B cells, macrophages, and dendritic cells, and are involved in the activation of T cells in the immune response.

The test utilizes fluorescently labeled beads that are coated with purified Class II HLA antigens. The patient’s serum or plasma is incubated with these beads, and if there are specific IgG antibodies against any of the Class II HLA antigens, they will bind to the corresponding beads. The beads are then analyzed using flow cytometry to determine which HLA antigens have antibodies bound to them.

The DSA-SAB Class II Test provides valuable information about the presence and specificity of IgG antibodies against Class II HLA antigens in transplant recipients. This information can help guide clinicians in assessing the risk of antibody-mediated rejection and making decisions regarding donor compatibility and immunosuppressive therapy.

Test Components and Price

Components: HLA Single Antigen Bead Assay for Class II IgG Antibodies DSA-SAB Class II Test

Price: AED 4680.0

Sample Condition

2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen. Give brief clinical history.

Report Delivery

10-12 days

Method

Luminex X-Map technology

Test Type

Transplantation

Doctor

Nephrologist

Test Department

Pre Test Information: Give brief clinical history.

Test Name HLA SINGLE ANTIGEN BEAD ASSAY FOR CLASS II IgG ANTIBODIES DSA-SAB CLASS II Test
Components
Price 4680.0 AED
Sample Condition 2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen. Give brief clinical history.
Report Delivery 10-12 days
Method Luminex X-Map technology
Test type Transplantation
Doctor Nephrologist
Test Department:
Pre Test Information Give brief clinical history.
Test Details

The HLA Single Antigen Bead Assay for Class II IgG antibodies (DSA-SAB Class II Test) is a laboratory test used in transplantation medicine to detect and identify specific antibodies against human leukocyte antigens (HLA) in the blood of transplant recipients.

HLA molecules are proteins found on the surface of cells that help the immune system distinguish between self and non-self cells. In transplantation, it is important to match the HLA antigens between the donor and recipient to minimize the risk of rejection. However, sometimes the recipient may develop antibodies against the donor’s HLA antigens, known as donor-specific antibodies (DSA), which can increase the risk of rejection and graft failure.

The DSA-SAB Class II Test specifically focuses on detecting and identifying IgG antibodies against Class II HLA antigens. Class II HLA antigens are found on antigen-presenting cells, such as B cells, macrophages, and dendritic cells, and are involved in the activation of T cells in the immune response.

The test utilizes fluorescently labeled beads that are coated with purified Class II HLA antigens. The patient’s serum or plasma is incubated with these beads, and if there are specific IgG antibodies against any of the Class II HLA antigens, they will bind to the corresponding beads. The beads are then analyzed using flow cytometry to determine which HLA antigens have antibodies bound to them.

The DSA-SAB Class II Test provides valuable information about the presence and specificity of IgG antibodies against Class II HLA antigens in transplant recipients. This information can help guide clinicians in assessing the risk of antibody-mediated rejection and making decisions regarding donor compatibility and immunosuppressive therapy.